Search Results for 'novartis'
-
Financial Reports
Financial Report: Novartis
Pharmaceutical sales up 2% driven by Entresto, Cosentyx and Zolgensma.Contract Pharma Staff 11.04.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
Novartis Expands Kymriah Manufacturing Footprint
Gets green light for commercial CAR-T cell therapy manufacturing site in Asia.Contract Pharma Staff 11.03.20
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances
REGENXBIO Achieves $80M Novartis Milestone
Zolgensma, which leverages REGENXBIO's NAV AAV9 vector, reaches $1 billion in sales.Contract Pharma Staff 10.27.20
-
Breaking News | Collaborations & Alliances
Elsevier, Novartis Collaborate on Risk Assessment Prediction Tool
To develop a safety margin risk assessment prediction tool, largely using PharmaPendium data.Contract Pharma Staff 10.22.20
-
Breaking News | Collaborations & Alliances | Facilities | Industry News | Parenterals | Solid Dosage/Creams/Ointments
Siegfried Acquires Two Pharma Manufacturing Sites from Novartis in Spain
Sites are specialized in the manufacturing of ophthalmic steriles as well as oral solid dosage forms and capsules used in inhalation devices.Contract Pharma Staff 10.02.20
-
Breaking News | cGMP Manufacture | Industry News
BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production
Will accelerate BioNTech’s efforts to scale-up commercial manufacturing capacity for its mRNA COVID-19 vaccine candidate BNT162.Contract Pharma Staff 09.17.20
-
Collaborations & Alliances | Drug Development
Sangamo, Novartis Partner to Develop Gene Therapies for Autism
Sangamo will receive $75M upfront and is eligible to receive up to $720M in potential milestones for three neurodevelopmental targets.Contract Pharma Staff 07.30.20
-
Breaking News | Industry News
Novartis Launches Portfolio of Meds for COVID-19 Treatment
Portfolio of 15 generic and OTC medicines from Sandoz will be sold at zero-profit to governments in eligible countries during the pandemic.Contract Pharma Staff 07.16.20
-
-
Breaking News | Collaborations & Alliances | Formulation Development
Vectura Earns $5M Novartis Milestone for Enerzair Breezhaler
Enerzair Breezhaler uses Vectura’s formulation IP, and is a first-in-class fixed-dose combination maintenance treatment for uncontrolled asthma.Contract Pharma Staff 07.07.20
-
Breaking News | Industry News
Novartis Halts COVID-19 HCQ Study
Discontinues hydroxychloroquine clinical trial based on slow enrollment, no safety issues have been reported or efficacy conclusions made.Contract Pharma Staff 06.22.20
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Trials & Filings
Novartis’ Kymriah Gets RMAT Designation
Investigational new indication to treat patients with relapsed or refractory follicular lymphomaContract Pharma Staff 04.22.20
-
The Supply Chain House of Cards
The COVID-19 pandemic exposes pressures on extended global supply chainsEmil W. Ciurczak, DoraMaxx Consulting 04.01.20
-
Drug Delivery
CEO Spotlight: Will Downie
Vectura’s chief executive talks trends in the inhaled-drug market, and the company’s transition into a CDMOTim Wright, Editor, Contract Pharma 04.01.20
-
Breaking News | Industry News
FDA Issues Emergency Approval for Anti-Malaria Drugs
HHS accepts donations of hydroxychloroquine sulfate, chloroquine phosphate as possible treatments for COVID-19 patients03.30.20
-
Breaking News | Industry News | Packaging & Tracking | Regulatory Affairs | Solid Dosage/Semi-solids
Novartis Recalls Sandimmune, Neoral Blister Packs Due to Packaging Failure
Corrective action plan to address blister packs that do not meet U.S. child-resistant packaging requirements, there are no quality or efficacy issues.03.19.20
-
Breaking News | Promotions & Moves
-
Bio News | Breaking News | Industry News | Promotions & Moves
-
Chemistry
Greener by Design
How new approaches to green chemistry are driving sustainable processes.Kenneth Ball, Commercial Operations Lead, Pfizer CentreOne 03.04.20
-
Logistics
Creating a Secondary Packaging Strategy
When is the ideal time to start?Ingo Schraut, Product & Service Manager, Vetter Pharma International GmbH 03.04.20
-
Breaking News | Chemistry | Drug Development | Industry News | Information Technology
Pistoia Alliance’s UDM Project Reaches Milestone
Latest UDM helps build comprehensive data model for chemical reactions to support Lab of The Future and AI adoption02.25.20
-
Drug Development
Major Drug Approvals of 2019
Abbvie, Novartis, Pfizer and J&J score big wins with blockbuster potentialOnline Exclusives Kristin Brooks, Contract Pharma 02.24.20
-
Bio News | Breaking News | Cold Chain Management | Industry News | Packaging & Tracking
Pelican BioThermal Opens Toronto Network Station
The Crēdo on Demand network station will service cold chain shipping rentals for the growing Canadian pharmaceutical industry02.14.20
-
Breaking News | Promotions & Moves
Aprecia Appoints Chief Scientific Officer
Dr. Matharu brings more than 20 years of industry experience02.03.20
-
Breaking News | Financial Reports
Financial Report: Novartis
Pharmaceuticals sales up 12% in the quarter driven by Entresto and Cosentyx01.30.20
-
Biosimilars
-
Realizing the Full Potential of Precision Medicine in Oncology
Innovation in oncology drug development is being driven by “precision medicine"Peter Larson, Executive Medical Director, Hematology-Oncology, Premier Research 01.28.20
-
Drug Development | R&D
Top Pharma M&A Deals of 2019
Drug manufacturers spent a record $342 billion on Mergers & AcquisitionsOnline Exclusives Kristin Brooks, Contract Pharma 12.23.19
-
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Industry News
Novartis to Acquire The Medicines Company for $9.7B
Adds cardiovascular drug inclisiran to portfolio, a potentially transformational investigational cholesterol-lowering therapy.11.28.19
-
-
Supply Chain
Supply Chain Disruptions
The implications of Sandoz’ recent recalls.Ed Silverman, Guest Columnist 10.15.19
-
Contract Pharma’s 20th Anniversary Retrospective
A look back a the pharma/biopharma industry and the future of outsourcing.Kristin Brooks, Managing Editor, Contract Pharma 10.15.19
-
Promotions & Moves
Avidity Biosciences Appoints President and CEO
Sarah Boyce brings extensive experience in the life sciences industry10.01.19
-
Cytotoxics and High Potency Manufacturing
-
Promotions & Moves
Jubilant Therapeutics Appoints President and CEO
Syed Kazmi's accomplished career includes 25 years in M&A, licensing, strategic collaborations, and R&D in specialty biotech and large pharma09.13.19
-
Biologics, Proteins, Vaccines | Cold Chain Management | Drug Development | Supply Chain
CAR T for Large Tumors: The Next Frontier?
Ryan Carpentier of Cryoport discusses the successes and the challenges these exciting new therapies presentRyan Carpentier, Executive Director of Business Development at Cryoport 09.10.19
-
-
Promotions & Moves
Provention Bio Appoints Clinical Development SVP
Dr. Kell will lead the PRV-031 program, including the oversight of the Phase III PROTECT study and support of regulatory submissions08.20.19
-
Bio News | Breaking News | Collaborations & Alliances | Industry News
AveXis, BIA Ink Gene Therapy Manufacturing Process Development Deal
BIA to provide expertise in next generation biomolecule purification processes and long-term supply of CIMmultus monolithic columns07.26.19
-
Top 25 Pharma and Biopharma Companies
(Based on 2018 Pharma/Biopharma Sales, in $U.S. Millions)Tim Wright & Kristin Brooks 07.18.19
-
cGMP Manufacture | Industry News
Catalent, AveXis Enter Long-term Strategic Mfg. Pact
AveXis will have dedicated manufacturing space at Paragon’s new commercial manufacturing center near Baltimore-Washington Int’l Airport07.16.19
-
-
-
-
The Top Companies Report
Combined sales for 2018 topped the $600 billion markTim Wright, Editor 07.15.19
-
Drug Development | Industry News | Trials & Filings
Amgen, Novartis and Banner Discontinue CNP520 in AD
An assessment of data identified worsening in some measures of cognitive function07.12.19
-
Promotions & Moves
Gilead Appoints CEO of Kite
Shaw brings extensive experience providing commercial, financial, strategic, medical and operations leadership across the biopharma industry07.12.19
-
-
Bio News | Breaking News | Facilities | Fill/Finish | Industry News
Lonza to Acquire Sterile Fill and Finish Facility from Novartis
First facility for Lonza’s Drug Product Services to cover sterile manufacturing for clinical production and commercial launches07.01.19
